HROW vs. HALO

In the year-to-date period, HROW achieves a 291.79% return, which is significantly higher than HALO's 23.65% return. Both investments have delivered pretty close results over the past 10 years, with HROW having a 18.43% annualized return and HALO not far behind at 17.99%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HROW Sharpe Ratio is 4.40, which is higher than the HALO Sharpe Ratio of 0.42. The chart below compares the historical Sharpe Ratios of HROW and HALO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither HROW nor HALO has paid dividends to shareholders.

The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO. For additional features, visit the drawdowns tool.

Harrow Health, Inc. (HROW) has a higher volatility of 27.27% compared to Halozyme Therapeutics, Inc. (HALO) at 25.49%. This indicates that HROW's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Harrow Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.